Protective effect of cardioplegia with poly (ADP-ribose) polymerase-1 inhibitor against myocardial ischemia-reperfusion injury: in vitro study of isolated rat heart model.

Published

Journal Article

Poly(ADP-ribose) polymerase (PARP)-1 inhibitor has been suggested to attenuate the ischemia-reperfusion injury. We investigated the protective effect of the cardioplegia with a PARP-1 inhibitor, 4-hydoxyquinazoline (4-HQ), against myocardial ischemia-reperfusion injury. Isolated rat hearts were perfused on a Langendorff apparatus and cardioplegically arrested for 90 min by perfusion with St. Thomas' Hospital solution (ST-solution). In the Group ST (n = 8), the hearts were arrested with the ST-solution alone. The Group HQ (n = 8) were treated with the ST-solution containing 4-HQ (10 µM) for cardioplegia. During reperfusion, the Group HQ showed significantly greater functional recovery of +dp/dt(max) (p = 0.005) and lower enzymatic leakage (p < 0.01). NAD(+) levels were also preserved higher in the Group HQ (p < 0.01). Immunohistochemical study revealed lesser extents of oxidative stress and apoptosis, in the Group HQ. Thus, addition of 4-HQ in the cardioplegia may provide a new intervention for myocardial protection against ischemia-reperfusion injury by decreasing NAD(+) consumption and suppressing oxidative stress.

Full Text

Cited Authors

  • Yamazaki, K; Tanaka, S; Sakata, R; Miwa, S; Oriyanhan, W; Takaba, K; Minakata, K; Marui, A; Ikeda, T; Toyokuni, S; Komeda, M; Ueda, K

Published Date

  • February 2013

Published In

Volume / Issue

  • 28 / 1

Start / End Page

  • 143 - 147

PubMed ID

  • 22168830

Pubmed Central ID

  • 22168830

Electronic International Standard Serial Number (EISSN)

  • 1475-6374

Digital Object Identifier (DOI)

  • 10.3109/14756366.2011.642373

Language

  • eng

Conference Location

  • England